Wednesday, July 8, 2026

pharma · Analgesia · Postoperative Pain · HRTX

Heron Therapeutics

Heron Therapeutics is a pharma organization headquartered in Cary, USA. It trades on NYSE under ticker HRTX. Primary therapeutic focus areas include Analgesia, Postoperative Pain, Chemotherapy-induced Nausea and Vomiting

100 Regency Forest Dr, Cary, North Carolina 27518, US HQ
1983 Founded
188 Employees
Public company Type
HRTX · NYSE Ticker
Company details
Status
Public
HQ
100 Regency Forest Dr, Cary, North Carolina 27518, US
Founded
1983
Employees
188
Programs
18
Drugs
17
Patents
46
Clinical program

Aprepitant injectable emulsion

Phase 2 · small molecule · COVID-19

Aprepitant injectable emulsion for COVID-19 is a Phase 2 program (small_molecule) at Heron Therapeutics with 1 ClinicalTrials.gov record(s).

← All Heron Therapeutics projects Phase 2 small molecule terminated

Internal code HTX-019-202

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Heron Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
COVID-19
Status
terminated
Trials
1